Research Publications

HCV RNA viral load assessments in the era of direct-acting antivirals.

Cobb B, Pockros PJ, Vilchez RA, Vierling JM

Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failure.

Foster GR, Zeuzem S, Andreone P, Pol S, Lawitz EJ, Diago M, Roberts S, Pockros PJ, Younossi Z, Lonjon-Domanec I, De Meyer S, Luo D, George S, Beumont M, Picchio G

Non-nucleoside analogue polymerase inhibitors in development.

Pockros PJ

Nucleoside/nucleotide analogue polymerase inhibitors in development.

Pockros PJ

Novel and combination therapies for hepatitis C virus.

Pockros PJ

What are the promising new therapies in the field of chronic hepatitis C after the first-generation direct-acting antivirals?

Hunt D, Pockros P

Management of anorectal symptoms associated with telaprevir.

Pockros PJ

Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa-2a/ribavirin.

Zeuzem S, Rodríguez-Torres M, Rajender Reddy K, Marcellin P, Diago M, Craxi A, Pockros P, Rizzetto M, Bernstein D, Shiffman ML, Lin A, Tatsch F, Hadziyannis S

Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection.

Gordon SC, Pockros PJ, Terrault NA, Hoop RS, Buikema A, Nerenz D, Hamzeh FM

Interferon-free hepatitis C therapy: how close are we?

Pockros PJ